Sarecycline Seysara denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sarecycline seysara are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Sarecycline (Seysara) for Quantity Limits

Blue Cross Blue Shield's quantity-limit denial means the plan has a policy restricting how much sarecycline can be dispensed within a defined time period — for example, limiting the supply to a set number of tablets per fill or per month. When a prescription exceeds that limit, the claim is denied for the amount above the threshold. Quantity limits are a formulary management tool and do not necessarily reflect a clinical judgment about your care.

### Why This Denial Is Appealable

Quantity limits can be appealed through a quantity-limit exception process when your prescriber documents a clinical reason why the standard limit is insufficient for your care. If your treatment plan, as documented in your chart, requires a quantity that exceeds the default limit, that clinical need is the basis of the appeal. Plans cannot apply quantity limits in a way that effectively denies medically necessary treatment.

### Federal Appeal Framework

• Quantity exception / internal appeal: File a quantity-limit exception request, which is typically treated as or paired with a formal internal appeal under ERISA §503 or ACA §2719. Deadlines appear on the denial notice.
• External review: After an adverse internal decision, you may request independent external review under ACA §2719, generally within about four months of the final denial.
• Expedited review: Available if delay in receiving the full prescribed quantity would cause clinical harm; request in writing.

### Concrete Appeal Steps

1. Obtain BCBS's published quantity-limit policy for sarecycline or its drug class from the member portal or by calling member services. 2. Confirm the exact quantity limit that is being applied and what quantity your prescriber ordered. 3. Ask your prescriber to document in a clinical note why the prescribed quantity is medically necessary — for example, a longer treatment duration supported by the treatment plan or a specific patient characteristic. 4. Submit a quantity-limit exception request with the prescriber's documentation. 5. If denied, file a formal internal appeal and, if needed, escalate to external review.

### Documentation to Gather

• Diagnosis and treatment plan: Chart notes confirming diagnosis, severity, and the planned treatment duration.
• Prescriber letter: A letter from the dermatologist or prescriber explaining the clinical rationale for the prescribed quantity, referencing the treatment plan and relevant guideline organization's general recommendations (e.g., the applicable AAD guideline on treatment duration), without stating specific numeric thresholds from the guideline.
• Pharmacy records: Prior fill history showing adherence and ongoing clinical need.
• Criteria mapping: Copy each requirement from BCBS's quantity-limit exception policy; provide the chart fact satisfying each requirement.

### Key Reminder

The exact quantity thresholds that trigger this denial — and the criteria for a quantity-limit exception — are specified in BCBS's formulary or coverage policy. Retrieve the current version directly from BCBS before preparing your appeal, and cross-reference every requirement against your prescriber's documentation.